Investing.com - Genmab AS reported on Wednesday fourth quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Genmab AS announced earnings per share of kr0.1653 on revenue of kr400.05M. Analysts polled by Investing.com anticipated EPS of kr0.148 on revenue of kr388.14M.
Genmab AS shares are down 13.42% from the beginning of the year and are trading at kr34.25 , down-from-52-week-high.They are under-performing the Nasdaq which is down 9.63% from the start of the year.
Genmab AS shares gained 1.03% in intra-day trade following the report.
Genmab AS follows other major Healthcare sector earnings this month
Genmab AS's report follows an earnings beat by UnitedHealth on Wednesday, January 19, 2022, who reported EPS of kr4.48 on revenue of kr73.74B, compared to forecasts EPS of kr4.3 on revenue of kr72.98B.
J&J had beat expectations on Tuesday, January 25, 2022 with fourth quarter EPS of kr2.13 on revenue of kr24.8B, compared to forecast for EPS of kr2.12 on revenue of kr25.28B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar